Neumora Therapeutic NMRA 深 滬
等待開盤 09-23 09:30:00 美东时间
0.7785
+0.087
+12.53%
華盛通- 最 高0.8111
- 今 開0.6961
- 成交量 321.19万股
- 最 低 0.69
- 昨 收 0.6918
- 總市值 1.46亿
- 52周最高 3.65
- 市盈率 靜 --
- 換手率 1.71%
- 52周最低 0.6805
- 委 比 43.39%
- 總股本 1.88亿
- 歷史最高 21.00
- 量 比 1.18
- 振 幅 17.51%
- 歷史最低 0.611
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
ANI Pharmaceuticals appoints Henry Gosebruch to its Board of Directors, leveraging his 30+ years of experience in biopharmaceutical strategy, business development, and finance to accelerate its transformation into a leading Rare Disease company. Gosebruch, formerly CEO of Lakefront Biotherapeutics and AbbVie's Chief Strategy Officer, will support ANI's growth initiatives. Samy Shanmugam resigns from the Board but remains in his executive role.
08-24 10:55
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share from the same period last year.
08-14 19:18
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences reported Q2 2026 financial results and business updates, highlighting the full enrollment of its Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, exceeding targets and on track for 2H 2027 topline data. The company refocused its strategic plan on ocular oncology, deprioritizing the NMIBC program while maintaining data collection. Organizational restructuring and leadership appointments were announced to align resour...
08-11 11:00
Why Is BioAge Labs Stock Sinking Friday?
BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies. William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial cast doubt...
08-01 01:24
Neumora advances NMRA-215 with positive toxicology results
Neumora Therapeutics, Inc. ( ($NMRA) ) just unveiled an announcement. On July 2...
07-27 19:28
Neumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026
Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215,...
07-27 19:03
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Neumora Therapeutics plans to submit an IND application for NMRA-215, a novel NLRP3 inhibitor for obesity and cardiometabolic diseases, in Q4 2026, following favorable results from a repeat 13-week rat toxicology study. The company believes prior unexpected adverse findings were unrelated to NMRA-215. NMRA-215 has shown promising preclinical efficacy, including significant weight loss and improvements in cardiometabolic biomarkers, supporting its...
07-27 11:00
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.
07-13 22:09
Datadog, EHang Holdings And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 1% on Monday. Shares of Datadog Inc (NASDAQ:DDOG) fell sharply in pre-market trading. Bernstein analyst Peter Weed downgraded Datadog from Outperform to Market Perform and raised the price target from $180 to $22...
07-06 20:02
